Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients The DISTAL-2 randomized trial

被引：28

作者：

Gebbia, Vittorio ^{[1
]}

Gridelli, Cesare ^{[2
]}

Verusio, Claudio ^{[3
]}

Frontini, Luciano ^{[4
]}

Aitini, Enrico ^{[5
]}

Daniele, Bruno ^{[6
]}

Gamucci, Teresa ^{[7
]}

Mancuso, Gianfranco ^{[1
]}

Di Maio, Massimo ^{[8
,9
]}

Gallo, Ciro ^{[10
]}

Perrone, Francesco ^{[9
]}

Morabito, Alessandro ^{[9
]}

机构：

[1] Univ Palermo, Palermo, Italy

[2] Azienda Sanitaria SGiuseppe Moscati, Avellino, Italy

[3] Azienda Osped Busto Arsizio, Saronno, VA, Italy

[4] Azienda Osped San Gerardo, Unita Operat Radioterapie & Oncol, Milan, Italy

[5] Azienda Osped C Poma, Mantua, Italy

[6] Azienda Osped G Rummo, Benevento, Italy

[7] Osped Umberto 1, Frosinone, Italy

[8] Osped N Giannettasio, Cosenza, Italy

[9] Ist Nazl Tumori, Unita Sperimentazioni Clin, Naples, Italy

[10] Seconda Univ, Naples, Italy

来源：

LUNG CANCER | 2009年 / 63卷 / 02期

关键词：

Non-small-cell lung cancer; Second-line therapy; Docetaxel; Gemcitabine; Vinorelbine; Capecitabine; PHASE-II TRIAL; THYMIDINE PHOSPHORYLASE; ANTITUMOR-ACTIVITY; BREAST-CANCER; GROWTH-FACTOR; CAPECITABINE; GEMCITABINE; VINORELBINE; IRINOTECAN; THERAPY;

D O I：

10.1016/j.lungcan.2008.05.027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Doublet chemotherapy is more effective than single-agent as first line treatment of advanced non-small-cell lung cancer (NSCLC). No reliable information instead is available on the effect of doublets in second line treatment. The aim of DISTAL-2 study was to compare two doublets containing docetaxel with single agent docetaxel as second line treatment of patients with NSCLC (ClinicalTrials.gov id.:.NCT00345059). Methods: NSCLC patients, aged <75, PS 0-2, who had failed platinum-based chemotherapy, were randomly assigned with a 3:1:1 ratio to: arm A, weekly docetaxel (33.3 mg/m(2) on days 1, 8,15 q 4 weeks); arm B, on days 1, 8 q 4 weeks) or plus weekly docetaxel (30 mg/m(2) on days 1, 8,15) plus gemcitabine (800 mg/m(2) vinorelbine (20 mg/m(2) on days 1, 8 q 4 weeks) depending on which of the two had been used in first line; arm C, weekly docetaxel (as in arm B) plus capecitabine (625 mg/m(2) twice daily on days 5-18 q 4 weeks). Primary end-point was overall survival (OS). Two comparisons were planned: arm B vs. A and arm C vs. A. Overall, 375 patients had to be randomized. Response was assessed by RECIST, quality of life (QoL) by EORTC questionnaires. Results: 84 patients were randomized from May 2005 to December 2006, when the trial was prematurely stopped due to the slow accrual. After 62 deaths, median OS was 40.0 weeks in arm A, 32.6 weeks in arm B (p=0.18 vs. A) and 39.7 weeks in arm C (p=0.90 vs. A). Response rate was 6.4, 16.7 and 5.3%, and median progression-free survival was 12.4,13.1 and 11.9 weeks, for arms A, B and C, respectively. Patients in arm B had significantly more grade 3-4 haematological and non-haematological toxicity compared to arm A, and patients in arm C had significantly more grade 3-4 non-haematological toxicity compared to arm A. No relevant differences were found in QoL analysis, with the exception of significant worsening in appetite, vomiting and hemoptysis for patients in arm B. Conclusion: Due to early termination, the trial does not have the planned statistical power. However, available data do not support the role of docetaxel-based combination chemotherapy as second line in advanced NSCLC. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：251 / 258

页数：8

共 39 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].